Stay updated with breaking news from Interferon Alpha. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Психолог по тревожным расстройствам объясняет, как не поддаться массовой панике на фоне негативных событий в мире.
© Javier Galeano/AP Medical students in laboratory of the Latin American School of Medicine in Havana. It's a medical school like no other: the largest of its kind in the world. The Latin American School of Medicine (ELAM) in Havana, Cuba hosts students from well over 100 countries and every year, dozens of American students are paid to go there to train as doctors. Paid, that is, by the Cuban government on the proviso that they return to the U.S. and serve underprivileged communities. Generally, students come from underprivileged backgrounds themselves and would not have been able to atten...
Industry > Industry monitor > Pharmaceuticals 23 April 2021 The Drug Controller General of India (DCGI) has granted Restricted Emergency Use Approval for Zydus Cadila’s Pegylated Interferon alpha-2b (PegIFN) or `Virafin’ for treating moderate Covid-19 infection in adults. A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during Covid, Virafin will help patients recover faster and avoid much of the complications, the company stated in a release. Virafin will be available on the prescription o...
Zydus In a big boost to the national effort against COVID-19, Ahmedabad-based pharmaceutical major Zydus Cadila on Friday (23 April) announced that the company has received Restricted Emergency Use Approval (EUA) from the Drug Controller General of India (DCGI) for the use of âVirafinâ, Pegylated Interferon alpha-2b (PegIFN,) in treating moderate COVID-19 infection in adults. The company has claimed that a single dose subcutaneous regimen of the Virafin developed by it can help patients recover faster and avoid complications if the drug is administered to them early on during COVID-...
April 23, 2021 Company claims the treatment reduces the hours of supplemental oxygen in the patients Cadila Healthcare Limited (Zydus Cadila) has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate Covid-19 infection in adults. Announcing the development, the company informed that the single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. “When administered early on during Covid, Virafin will help pa...